IFNG-AS1: A Promising Drug Target / Biomarker (G100885789)

Target Name: IFNG-AS1

NCBI ID: G100885789

IFNG-AS1

Other Name(s): IFNG-AS1 variant 1 | Tmevpg1 | IFNG antisense RNA 1 | GS1-410F4.2 | NEST

IFNG-AS1: A Promising Drug Target / Biomarker

The interleukin-8 (IL-8) signaling pathway is a crucial factor in the regulation of immune and inflammatory responses. IL-8 is a cytokine that is produced by various cell types in response to an infection or injury and plays a key role in the recruitment of immune cells to the site of inflammation. The IL-8 signaling pathway is also involved in the regulation of cell growth, apoptosis, and angiogenesis, and is Therefore, it is of great interest as a drug target or biomarker.

IFNG-AS1: A Potential Drug Target

IFNG-AS1 is a protein that is expressed in various cell types, including immune cells, and is involved in the regulation of the IL-8 signaling pathway. IFNG-AS1 functions as a negative regulator of the IL-8 signaling pathway, preventing the production of IL-8 and inhibiting its effects on downstream signaling pathways.

IFNG-AS1 is a single transmembrane protein that is characterized by the presence of an N-terminal transmembrane domain, a catalytic center, and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is known as the extracellular domain, and it is involved in the formation of the extracellular matrix (ECM) and in the regulation of cellular signaling pathways. The catalytic center is located in the middle of the protein and is responsible for the regulation of the activity of the IL-8 receptor. The C-terminal cytoplasmic domain is involved in the regulation of cellular signaling pathways and in the formation of the cytoplasmic environment for the IL-8 receptor.

IFNG-AS1 is a potent inhibitor of the production of IL-8 and has been shown to have a positive impact on the expression of anti-inflammatory genes. IL-8 is a potent chemoattractant for immune cells, and it has been shown to play a key role in the recruitment of immune cells to the site of inflammation. The inhibition of IL-8 production by IFNG-AS1 would lead to a reduction in the number of immune cells recruited to the site of inflammation, thereby limiting the inflammatory response.

IFNG-AS1 has also been shown to have a positive impact on the expression of anti-inflammatory genes. IL-8 is a potent chemoattractant for immune cells, and it has been shown to play a key role in the recruitment of immune cells to the site of inflammation. The inhibition of IL-8 production by IFNG-AS1 would lead to a reduction in the number of immune cells recruited to the site of inflammation, thereby limiting the inflammatory response.

IFNG-AS1 is also involved in the regulation of cell growth and apoptosis. The production of IL-8 is closely associated with the regulation of cell growth and apoptosis, and IFNG-AS1 plays a key role in this regulation. IFNG-AS1 has been shown to promote the growth of cancer cells and to inhibit the apoptosis of these cells.

IFNG-AS1 is also involved in the regulation of angiogenesis. Angiogenesis is the process by which new blood vessels are formed, and it is closely associated with the production of IL-8. IFNG-AS1 has been shown to promote the production of new blood vessels and to inhibit the regression of these vessels.

IFNG-AS1 is a unique protein that is involved in the regulation of the IL-8 signaling pathway and has a great potential as a drug target or biomarker. The inhibition of IL-8 production by IFNG-AS1 would lead to a reduction in the inflammatory response and would have a positive impact on the expression of anti-inflammatory genes. It also plays a key role in the regulation of cell growth, apoptosis, and angiogenesis, and has been shown to promote the growth of cancer cells and to inhibit the apoptosis of these cells. Therefore, IFNG-AS1 is a

Protein Name: IFNG Antisense RNA 1

The "IFNG-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFNG-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets